Vimarsana
Biggest News Aggregation in the World

Martin Akerman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Martin Akerman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Martin Akerman Today - Breaking & Trending Today

Insilico Medicine's leadership to address key challenges in AI drug discovery at BIO Convention - Vimarsana News

Insilico Medicine's leadership to address key challenges in AI drug discovery at BIO Convention

Leadership from clinical stage artificial intelligence (AI)-powered drug discovery company Insilico Medicine ("Insilico") will attend the BIO International Convention in San Diego June 3-6 and present on key issues facing AI drug discovery.

Envisagenics Validates AI/ML Approach for RNA Target Identification and SSO Therapeutic Development - Vimarsana News

Envisagenics Validates AI/ML Approach for RNA Target Identification and SSO Therapeutic Development

BioPharma

Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D - Vimarsana News

Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D

Cold Spring Harbor spinout Envisagenics will apply its AI technology to multiomics data in pursuit of new therapies for acute myeloid leukemia and other hematopoietic cancers.

Envisagenics, Cancer Research Horizons, and Queen Mary University of London Announce Strategic Collaboration Agreement - Vimarsana News

Envisagenics, Cancer Research Horizons, and Queen Mary University of London Announce Strategic Collaboration Agreement

/PRNewswire/ -- Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced...

Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D - Vimarsana News

Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D

Cold Spring Harbor spinout Envisagenics will apply its AI technology to multiomics data in pursuit of new therapies for acute myeloid leukemia and other hematopoietic cancers.